Navigation Links
Artificial Pancreas can Prevent the Development of Hypoglycemia
Date:6/18/2010

LONDON, June 18, 2010 /PRNewswire/ -- An article recently published in The Lancet reports that using an artificial pancreas system overnight can significantly reduce the risk of nocturnal hypoglycemia in children and adolescents with type 1 diabetes.(1) Moreover, the first clinical trial of an artificial pancreas system delivering both insulin and glucagon has shown that this system can prevent development of hypoglycemia.(2) The latest issue of the journal Diabetic Hypoglycemia (http://www.hypodiab.com) reviews advances in artificial pancreas design and production in further detail.

Dr Roman Hovorka, a leading artificial pancreas researcher and author of the Lancet paper(1) discusses developments in the field of closed-loop insulin delivery and reviews system components and challenges to the introduction of this technology into clinical practice, including the need for superfast-acting insulin analogs, dual hormone approaches to accelerate insulin absorption, and optimization of the clinical infrastructure to support the use of closed-loop systems.

Professor Simon Heller's related editorial details how technological developments supporting diabetes self-management have so far failed to lead to major improvements in glycemic control or to consistently reduced rates of severe hypoglycemia. He explains that one reason may be the requirement for patients to estimate both basal and prandial insulin doses, which can be demanding for many patients and may lead to ineffective diabetes self-management. Professor Heller discusses how the introduction of closed-loop systems might address this issue.

References

(1) Hovorka R, Allen JM, Elleri D, et al. Manual closed-loop insulin delivery in children and adolescents with type 1 diabetes: a phase 2 randomised crossover trial. The Lancet 2010:375(9716):743-51.

(2) El-Khatib FH, Russell SJ, Nathan DM, et al. A Bihormonal Closed-Loop Artificial Pancreas for Type 1 Diabetes. Sci Transl Med 2010:2(27):27ra27, published online 14 April 2010.

About Diabetic Hypoglycemia

Published by ESP Bioscience (Sandhurst, UK), Diabetic Hypoglycemia is an influential online diabetes journal led by Editor-in-Chief Professor Brian Frier (Edinburgh, UK), with Associate Editors: Professor Simon Heller (Sheffield, UK), Professor Christopher Ryan (Pittsburgh, USA) and Dr Rory McCrimmon (Dundee, UK). Published three times annually, Diabetic Hypoglycemia provides an interactive forum for the sharing of practical knowledge and opinions in the field of hypoglycemia.

To explore Diabetic Hypoglycemia, please take the guided tour: http://www.hypodiab.com/Teaser/hypodiab.html.

Diabetic Hypoglycemia is published by ESP Bioscience, supported by an unrestricted educational grant from Novo Nordisk A/S (Bagsvaerd, Denmark).

    Contact:

    Editorial Office
    E: enquiries@hypodiab.com
    T: +44(0)1344-762531
    F: +44(0)203-0514753



'/>"/>
SOURCE ESP Bioscience
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Scientists create artificial mini black hole
2. Cleveland researchers use natural and artificial sheaths to mend traumatic bone loss
3. First step to converting solar energy using artificial leaf
4. Scientists moving closer to artificial noses
5. Assembling cells into artificial 3-D microtissues, including a tiny gland
6. Scientists restore movement to paralyzed limbs through artificial brain-muscle connections
7. "Put Down the BBQ Ribs, We've Found You a Donor Heart," Nurse Tells Patient : Ohio Father near Death Gets Second Chance at Life with CardioWest™ temporary Total Artificial Heart
8. Arbios Sells HepatAssist Bioartificial Liver System to HepaLife Technologies, Inc.
9. CardioWest™ Artificial Heart Approved For Highest Reimbursement in CMS History : Plus Up To $53,000 New Technology Add-on Payments
10. Stretchable silicon camera next step to artificial retina
11. Memory in artificial atoms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... Coral Springs, FL (PRWEB) , ... August 17, ... ... today announced that the stock market news outlet had provided a research update ... the company's nasally administered TRT product. , According to Soulstring, prescription rates for ...
(Date:8/16/2017)... Ca (PRWEB) , ... August 16, 2017 , ... ... by changing into a different cell type. Many treatments for specific cancers, such ... prominent example of targeted treatment is androgen deprivation therapy for advanced prostate cancer. ...
(Date:8/16/2017)... 2017  This year,s edition of the Inc. 5000 features a now-familiar ... solutions, has made the list for the third year in a row. ... private companies based on a set of quantitative metrics. In addition, BioPoint ... companies in the Bay State . ... Inc. 5000 ...
(Date:8/15/2017)... ... August 15, 2017 , ... Nanomedical ... and biotherapeutics development, announces the launch of the new NHS Agile biosensor ... kinetic binding data for a wide range of molecules, including small and large ...
Breaking Biology Technology:
(Date:4/4/2017)... , April 4, 2017   EyeLock LLC ... announced that the United States Patent and Trademark Office ... broadly covers the linking of an iris image with ... transaction) and represents the company,s 45 th issued ... patent is very timely given the multi-modal biometric capabilities ...
(Date:3/30/2017)... The research team of The Hong Kong Polytechnic University (PolyU) ... ground breaking 3D fingerprint minutiae recovery and matching technology, pushing contactless ... use in identification, crime investigation, immigration control, security of access and ... ... A research team led by Dr Ajay Kumar ...
(Date:3/28/2017)... , March 28, 2017 ... Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video ... and Region - Global Forecast to 2022", published by ... in 2016 and is projected to reach USD 75.64 ... 2017 and 2022. The base year considered for the ...
Breaking Biology News(10 mins):